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CTLA-4:  A Negative Regulator o f  Auto immune Disease 
By Nitin J. Karandikar,* Carol L.Vanderlugt,* Theresa L.Walunas,* 
Stephen D. Miller,*5 and Jeffrey A. Bluestone*g 
From the *Department ofMicrobiology-Immunology andInterdepartmental Immunobiology Center, 
Northwestern University Medical School, Chicago, Illinois 6061 I; and *The Ben May Institute and 
the Committee of Immunology, The University of Chicago, Chicago, Illinois 60637 
Summary 
CTLA-4, a CD28 homologue xpressed on activated T cells, binds with high affinity to the 
CD28 ligands, B7-1 (CD80) and B7-2 (CD86). This study was designed to examine the role of 
CTLA-4 in regulating autoimmune disease. Murine relapsing-remitting experimental utoim- 
mune encephalomyelitis (R-EAE) is a demyelinating disease mediated by PLP139-151-specific 
CD4 + T cells in sJL/J mice. Anti-CTLA-4 mAbs (or their F(ab) fragments) enhanced in vitro 
proliferation and pro-inflammatory c tokine production by PLP139-151-primed lymph node 
cells. Addition of either eagent to in vitro activation cultures potentiated the ability of T cells 
to adoptively transfer disease to naive recipients. In vivo administration of anti-CTLA-4 mAb 
to recipients of PLP139-151-specific T cells resulted in accelerated and exacerbated disease. Fi- 
nally, anti-CTLA-4 treatment of mice during disease remission resulted in the exacerbation of
relapses. Collectively, these results suggest that CTLA-4 mediates the downregulation fongo- 
ing immune responses and plays a major role in regulating autoimmunity. 
T cell activation requires the delivery of at least two sig- nals to the T cell by the antigen-presenting cell 
(APC). One signal is antigen-specific and is provided by the 
ligation of the T cell receptor (TClq.) by antigen-MHC 
complexes, whereas the second "costimulatory" signal may 
be provided by the B7 family of molecules, B7-1 (CD80) 
or B7-2 (CD86), expressed on the APC. Interactions be- 
tween CD28 on the T cell and the B7 molecules on the 
APC are critical, both in vivo and in vitro, in preventing T 
cell unresponsiveness (1-4). The discovery of the CD28 
homologue, cytotoxic T lymphocyte associated molecule~4 
(CTLA-4), by subtractive mRNA cloning of cytotoxic T 
cells (5) has increased the complexity of costimulatory inter- 
actions. CTLA-4 binds with higher affinity to the B7-1 and 
B7-2 molecules (6). CTLA-4Ig, a soluble recombinant 
form of CTLA-4, is a potent inhibitor of B7/CD28 inter- 
actions and inhibits in vivo antigen-specific responses (2, 3, 
7, 8). However, the regulatory function of the native 
CTLA-4 molecule on the T cell surface has only recently 
been appreciated. 
The cytoplasmic tail of human and murine CTLA-4 is 
highly conserved (9), suggesting that it is involved in an 
important signaling function. Surface xpression of CTLA-4 
seems to be a tightly regulated event with transient expres- 
sion on activated T cells, peaking at 48-72 h after activa- 
tion (10, 11). Initial studies suggested that anti-CTLA-4 
Drs. Miller and Bluestone are co-senior authors. 
antibodies could synergize with anti-CD3 and anti-CD28 
to enhance T cell proliferation (10, 12). Thus, it was con- 
cluded that CTLA-4 was an additional costimulatory mole- 
cule that had functions cooperative with those of CD28. 
However, recent studies have indicated that CTLA-4 may, 
in fact, serve as a negative regulator o fT  cell activation. We 
have shown that soluble anti-CTLA-4 mAb as well as its 
F(ab) fragments increased T cell proliferation in murine 
ML1L responses (11). Additionally, intact cross-linked anti- 
CTLA-4 mAb, but not its F(ab) fragments, could inhibit 
proliferation i  T cells stimulated with anti-CD3 and anti- 
CD28 (11, 13). Thus, it is likely that CTLA-4 functions to 
downregulate T cell responses such that blockade of CTLA- 
4/B7 interaction results in enhanced T cell activation. Other 
studies also support a negative regulatory role for CTLA-4. 
Cross-linking of CTLA-4 after the ligation of CD3 and 
CD28 strongly inhibited proliferation and IL-2 production 
(14). In vivo treatment of mice with anti-CTLA-4 was 
shown to enhance clonal expansion of antigen-specific T 
cells after immunization (15) and enhance anti-tumor im- 
munity (16). In fact, CTLA-4 knockout mice express a 
lymphoproliferative disorder esulting in massive infiltra- 
tion of several organs leading to early death (17, 18). To- 
gether, these studies upport an essential role for CTLA-4 
in the downregulation fpotentially autoaggressive T cells. 
The present study was conducted to directly examine the 
role of CTLA-4 in regulating autoantigen-specific responses 
in autoimmune disease. Relapsing-remitting experimental 
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autoimmune ncephalomyelitis (R-EAE) is a well-estab- 
lished nmrine model for multiple sclerosis (MS) character- 
ized by CD4 + T cell-mediated demyelination i the cen- 
tral nervous ystem (CNS) (19). R -EAE is induced in SJL/J 
mice by immunization with the immunodominant epitope 
on proteolipid protein (PLP139-151) or by the adoptive 
transfer of PLP139-151-specific T cells (20). The clinical 
disease is characterized by an acute paralytic phase followed 
by recovery and subsequent relapses accompanied by de- 
velopment of  T cell responses to endogenous epitopes on 
myelin proteins (e.g., PLP178-191), a phenomenon termed 
epitope spreading (21, 22). CD28/B7-mediated costimula- 
tory interactions play a major role in the establishment and 
progression of  P,-EAE. Treatment of  mice with CTLA-4Ig 
has been shown to inhibit disease induction (8). Anti-B7-1 
or anti-B7-2 treatments have differential effects on autoim- 
mune diseases including R-EAE (23, 24) and autoimmune 
diabetes (25). Together, these studies emphasize the com- 
plexity of  costimulatory interactions between B7 molecules 
and CD28 or CTLA-4.  In this study, we have directly ad- 
dressed the role of CTLA-4 in modulating PLP 139-15 l -spe- 
cific T cell responses and in regulating disease using an anti- 
CTLA-4 mAb, known to prevent CTLA-4/B7 interactions. 
Both intact Ig and F(ab) fragments had similar effects in all 
the responses tudied, suggesting that these reagents were 
blocking CTLA-4-mediated events. First, ant i -CTLA-4 
mAb enhanced in vitro proliferation and production of  
pro-inflammatory c tokines by PLP139-151-primed lymph 
node ceils. Second, addition o fant i -CTLA-4 to in vitro ac- 
tivation cultures resulted in potentiation of  the ability of these 
cells to adoptively transfer R-EAE to naive recipients. Third, 
in vivo blockade of  CTLA-4 in recipient mice, after adop- 
tive transfer of  primed cells, also resulted in exacerbation of  
disease. Finally, treatment of  mice during remission, after 
the acute phase of  R.-EAE resulted in greater incidence and 
severity of  relapses. These results indicate that CTLA-4 has 
an important role in the downregulation o fT  cell responses 
in autoimmune disease and may be a major regulatory 
player in the control of ongoing immunopathology. 
Materials and Methods 
Mice. Female SJL/J mice, 6-7 wk old, were purchased from 
Harlan Laboratories (Indianapolis, IN), housed in the Northwest- 
ern animal care facility, and maintained on standard laboratory food 
and water ad libitum. Paralyzed mice were afforded easier access 
to food and water. 
Peptides. PLP139-151 (HSLGKWLGHPDKF) was purchased 
from Peptides International (Louisville, KY). Amino acid compo- 
sition was verified by mass spectrometry and purity (>98%) was 
assessed by HPLC. 
In Vitro Proliferation and Cytokine Assays. Mice were immu- 
nized subcutaneously with 100 ~1 of a Complete Freund's Adju- 
vant (CFA) emulsion containing 200 ~,g of Mycobacterium tubercu- 
losis H37Ra (Difco Labs. Inc. Detroit, MI) and 25 btg of 
PLP139-151 distributed over three spots on the flank. On day 
10, draining lymph node cells were harvested and cultured in 96- 
well microtiter plates at a density of 5 • 105 cells/well in a total 
volume of 200 ~xl Dulbecco's Modified Eagle Medium (DME) 
containing 7% fetal bovine serum, 1 mM glutamine, 1% Pen- 
Strep, 1 mM nonessential mino acids and 5 X 10 -5 M 2-mer- 
captoethanol (complete DME-7; all products from Sigma Chem. 
Co., St. Louis, MO). Cells were allowed to incubate at 37~ for 
60 min with the indicated antibodies (10 ~g/ml) before the indi- 
cated oses of antigen were added. Cultures were pulsed with 1 IxCi 
of [3H]TdR after 72 h, harvested at 96 h and [3H]TdR uptake 
determined by scintillation counts. Results are expressed as mean 
of triplicate cultures -+ SEM (background counts subtracted). Su- 
pernatants collected at 24 and 48 hours from replicate cultures 
were assayed for IL-2, IL-4, and IFN-y levels using ELISA Mini- 
Kits (Endogen, Cambridge, MA). Minimal detection limits of the 
assays were "~ pg/ml for IL-2 and IL-4 and 30 pg/nfl for IFN-% 
Flow Cytometry. FACS | analysis was performed using the 
FACScan | flow cytometer as described previously (11, 24). PE- 
conjugated anti-CD3 and FITC-conjugated control Ig were pur- 
chased from PharMingen (La Jolla, CA). 
Induction of R-EAE by Active Immunization with PLP139- 
151. Mice were immunized with 80 txg PLP139-151 in CFA 
as previously described (20). 
Adoptive Transfer qfR-EAE. Donor mice were immunized 
with 25 ~g of PLP139-151 in CFA. Draining lymph node cells 
were harvested on day t0 and cultured in either T25 (total vol- 
ume: 15 ml) or T75 (30 ml) flasks at 8 • 1() ~' cells/ml with 20 
#,g/ml of PLP139-151. In antibody-containing cultures, cells 
were incubated at 37~ for 60 rain with the indicated mAbs (11) 
L~g/ml) before the addition of antigen. On day 4, cells were 
washed in PBS, counted, and transferred i.p. into naive recipients 
in a total volume of 0.5 ml PBS. Recipient mice received a sub- 
optimal dose of 6-7 • 106 live cells each. 
Antibody Treatments. The following mAbs were employed: 
hamster control g (Cappel Research Products, Cochranville, PA) 
and the anti-CTLA-4 mAb (UCll-4F10) (11). Antibodies and 
F(ab) fragments were produced and purified as previously de- 
scribed (11, 25). Mice were treated, as indicated, either starting 
on the day of adoptive transfer or after recovery from the initial 
paralytic episode of R-EAE (~25 d post-immunization). 50 txg 
of antibody was administered i.p. every other day for five treat- 
ments (250 txg total) and mice were monitored for clinical signs 
of disease for an additional 20-40 d. 
Clinical Evaluation. Clinical severity was assessed on a 0 to 5 
scale as described (24). The data are plotted as the daily mean 
clinical score for all animals in a particular t eatment group. A re- 
lapse was defined as a sustained increase of at least one full grade 
in clinical score after the animal had previously improved at least 
a full clinical score and had stabilized. Mean maximal severity is 
the mean of the highest clinical score reached by mice within an 
experimental group which displayed clinical signs. 
Statistical Analyses. Comparison of the percentage of animals 
showing clinical disease and/or relapses between any two groups 
of mice were analyzed by X 2 using Fisher's exact probability. 
Comparisons of the mean day of onset of disease/relapse, and 
mean peak disease severity between any two groups of mice were 
analyzed by the Student's t test. P values <0.05 were considered 
significant. 
Results and Discussion 
Anti -CTLA-4 mAb Enhances PLP139-151-Specific In Vitro 
Proliferative and Cytokine Responses. Recent in vitro stud- 
ies have employed allogeneic MLR or anti-CD3 stimula- 
tion to assess the expression and function of  CTLA-4 on T 
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Anti-CTLA-4 mAb enhances in vitro proliferation a d cy- Figure 1. 
tokine production by PLP139-151-primed lymph node cells. (A) Drain- 
ing lymph node cells from PLP139-151/CFA-primed mice were cultured 
with 0.5 btM PLP139-151 and 10 b~g/ml of control or anti-CTLA-4 anti- 
bodies. Data represents the mean thymidine uptake of triplicate cultures 
and is plotted as A counts per minute + SEM (background counts [1712 + 
138] subtracted). These results are representative of six separate experi- 
ments. (B and C) Supernatants from replicate experiments were collected 
after 24 h of culture and assayed for 1L-2 and IFN-7 levels by ELISA. 
Data is plotted as mean cytokine l vels in pg/ml + SD at a peptide dose 
of 0.5 I-tM (IL-2) or 15 la, M (IFN-~/). Results are representative of three 
separate experiments. 
cells (10, 11, 14). To address the functional role of CTLA-4 
in nominal antigen-specific immune responses, mice were 
immunized with the immunodominant  PLP139-151 epi- 
tope and the effects of anti-CTLA-4 mAb (10 Ixg/ml) on 
in vitro proliferation and cytokine production by primed 
lymph node cells were determined. As seen in Fig. 1 A, the 
anti-CTLA-4 mAb significantly enhanced PLP139-151- 
specific proliferation. Higher concentrations of antibodies 
enhanced proliferative responses even further (data not 
shown). 24-h supematants from replicate cultures were as- 
sayed for IL-2, IL-4, and IFN-"v levels by ELISA. Anti- 
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Figure 2. Addition ofanti-CTLA-4 ]nAb to in vitro activation cultures 
enhances the ability to transfer R-EAE. Control or anti-CTLA-4 anti- 
bodies were added to in vitro activation cultures of PLP139-151-primed 
cells. On day 4, 6 X 106 total ive cells were transferred i.p. into naive re- 
cipients. Mice were then graded for clinical signs of R-EAE. Data is plot- 
ted as mean clinical score vs. days post-transfer. Disease incidences in the 
different groups were 4/7(Control), 6/6 (anti-CTLA-4) and 5/6 (anti- 
CTLA-4 F(ab)). Mean days of onset were 17.8, 12.5", and 14.2" d respec- 
tively (*P <0.05). Figures in parentheses indicate mean maximal c inical 
severity in each group (*P <0.05). Results are representative of four sepa- 
rate experiments. 
CTLA-4 mAb resulted in significantly enhanced IL-2 and 
IFN-y production (Fig. 1, B and C). No IL-4 was detected 
in any of the supernatants (data not shown). Similar pat- 
terns of enhanced proliferation and cytokine production 
were seen with varying peptide doses and after varying cul- 
ture times. The F(ab) fragments and the intact anti-CTLA-4 
antibody had the same enhancing effect, consistent with 
previous tudies (11, 15), suggesting that the enhancement 
of proliferation and cytokine production was due to the 
blockade of CTLA-4-mediated downregulatory events. 
Addition of Anti -CTLA-4 mAb to In Vitro Activation Cul- 
tures Enhances the Ability of PLP139-151-specific T Cells to 
Transfer R-EAE to Naive Recipients. We next tested whether 
blockade of CTLA-4/B7 ligation altered the generation of 
encephalitogenic PLP139-151-specific cells. PLP139-151- 
primed lymph node cells were activated in vitro in the 
presence of control lg or anti-CTLA-4 antibodies. En- 
cephalitogenicity of the resulting cells was then assessed by 
the expression of clinical disease after the adoptive transfer 
of a suboptimal dose of 6 • 106 viable cells to naive recipi- 
ents. Cells cultured with either anti-CTLA-4 or its F(ab) 
fragments were significantly more efficient at transferring 
R-EAE (Fig. 2). Mice receiving anti-CTLA-4-treated cells 
demonstrated an accelerated isease course (mean day of 
onset: 12.5" d and 14.2" d in antibody-treated groups vs. 
17.8 d in controls; *P <0.05) and a higher mean maximal 
disease severity (2.3 mean peak score in controls vs. 2.8 in 
the anti-CTLA-4-treated group and 3.4" in the F(ab)- 
treated group; *P <0.05). These results indicate that the 
blockade of CTLA-4/B7 interactions in the activation cul- 
tures resulted in an enhanced encephalitogenicity of the 
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cells transferred to naive recipients. Since ant i -CTLA-4 
mAb treatment also resulted in elevated proliferation and 
cytokine production by PLP139-151-specific T cells (Fig. 1), 
the enhanced isease course may be due to the transfer of  a 
higher number of  effector T cells and/or  of  effector cells 
capable of  producing enhanced levels of  pro-inflammatory 
cytokines. 
In Vivo Treatment with Anti-CTLA-4 mAb Exacerbates 
Adoptive R-EAE. We next examined whether CTLA-4-  
mediated events downregulated PLP139-151-specific T
cells in vivo. Activated PLP139-151-specific cells were adop- 
tively transferred to naive SjL/ j  recipients. Recipient mice 
were  then treated with control Ig, intact anti-CTLA-4, or 
ant i -CTLA-4 F(ab) fragments. Ant i -CTLA-4 mAb treat- 
ment exacerbated clinical disease (Fig. 3). Disease onset was 
accelerated (mean day of  onset (MDO): 7.0* d in anti- 
CTLA-4 treated group vs. 13.0 d in controls; *P <0.01) 
and the mean maximal severity of  the ant i -CTLA-4-  
treated groups was significantly greater (3.0 in controls vs. 
4.6* in anti -CTLA-4-treated groups; *P <0.01). In vivo 
treatment with ant i -CTLA-4 F(ab) fragments imilarly ac- 
celerated and exacerbated disease with a MDO of  10.0" d 
and a mean maximal severity of  3.7*; *P <0.05 (data not 
shown). Thus, it appears that CTLA-4-mediated events play 
a role in the downregulation of  the autoimmune ffector 
functions and/or  the in vivo expansion of  the adoptively 
transferred cells. Flow cytometric analyses of  PLP139-151- 
primed lymph node cells activated in culture showed up- 
regulation of  surface CTLA-4 expression on T cells (data 
not shown). Lymph node cells taken ex vivo from primed 
mice showed little CTLA-4 expression (time 0 h) which 
peaked after in vitro activation at about 72 h of  culture, as 
described before in other systems (11). At the time of  adop- 
tive transfer (96 h), a small, but significant population 
("~ of  T cells, showed surface CTLA-4 expression. 
Treatment of  the recipient animals starting on the day of  
transfer could result in the enhancement of  pro-inflamma- 
tory phenomena due to blockade of  CTLA-4-mediated 
downregulatory events in this population of  effector cells, 
or on other T cells within the transfer population which 
may upregulate CTLA-4 after presentation of  self peptides 
in the CNS. 
Anti-CTLA-4 mAb Treatment Exacerbates Relapses in 
R-EAE. R-EAE induced by immunization with PLP139- 
151 exhibits a relapsing and remitting disease course. The 
acute phase of  disease is due to the activity o fCD4 + T cells 
specific for the PLP139-151 epitope. However, we have 
recently shown (21) that the primary disease relapse is prin- 
cipally due to the activity of  T cells specific for an endoge- 
nous, non-cross-reactive epitope on PLP (PLP178-191) 
which are activated as a result of  recognition of  myelin 
epitopes released uring acute disease, aphenomenon known 
as epitope spreading. Tolerization of  PLP178-191-specific 
T cells (unpublished observations) or inhibition of  PLP178- 
191-specific responses by the blockade of  BT- l -mediated 
costimulatory signals during disease remission blocks disease 
relapses (24). To assess the role of  CTLA-4 in disease re- 
lapses, mice were treated with ant i -CTLA-4 mAb during 
remission, i.e., after they had recovered from the acute 
phase of active disease. Ant i -CTLA-4 treatment resulted in 
an increased isease severity and a higher incidence of re- 
lapses (Fig. 4). Four out of  the seven mice in the control 
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Figure 3. In vivo CTLA-4 blockade xacerbates adoptive R-EAE. 
1<-EAE was initiated by adoptive transfer of PLP 139-151 -specific T cells. 
Starting on the day of transfer, mice were treated i.p. with either control 
or anti-CTLA-4 mAbs and graded for clinical signs of EAE. Data is plot- 
ted as the mean clinical score vs. days post-transfer. Disease incidences 
were 8/8 (control group) and 8/8 (anti-CTLA-4-treated group). Mean 
days of onset were 13.0 and 7.0* d, respectively (*P <0.01). Figures in 
parentheses indicate mean peak clinical severity in each group (*P <0.01). 
Results are representative of three separate experiments. 
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Figure 4. Anti-CTLA-4 treatment exacerbates disease relapses in 
R-EAE. Active R-EAE was induced by priming with PLP139-151/ 
CFA. After recovery from the acute phase of disease ('-~ d post immu- 
nization), mice were treated with either control Ig or intact anti-CTLA-4 
mAb. Data is plotted as the relapse rate (total nmnber of relapses in a 
group divided by the total number of mice in that group) vs. days post- 
treatment initiation. 4/7 mice in the control group showed relapses, 
whereas 6/6 mice in the anti-CTLA-4-treated group relapsed (two mice 
relapsed two times each making atotal of 8 relapses in6 mice). Figures in 
parentheses indicate the mean peak clinical score of the relapses. These re- 
suits are representative of two separate experiments. *Number of relapses 
are significantly greater than that of the hamster Ig controls, P <0.05. 
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group showed relapses whereas six out of  six mice in the 
anti-CTLA-4 treated group relapsed, with two mice show- 
ing two relapses each (P <0.05). 
Collectively, the data presented in this paper support he 
hypothesis that CTLA-4 is a major negative regulator of  
autoimmune T cell function both in vitro and in vivo and 
emphasizes the complicated nature of  costimulatory inter- 
actions. We have shown that the blockade of CTLA-4 in- 
teractions with its ligands resulted in the enhancement of  
every effector function studied, including proliferation, 
pro-inflammatory cytokine production, encephalitogenic- 
ity, and the ability to maintain ongoing autoimmune dis- 
ease. These results are consistent with a model of  costimu- 
latory interactions, where initial activation of  T cells after 
antigen exposure is mediated by CD28/B7 interactions and 
leads to the proliferation and differentiation of  effector T 
cells. Activated T cells express CTLA-4 on their surface, 
which can bind the same B7-family ligands with higher af- 
finity and result in the downregulation of  the T cell re- 
sponse. The net T cell response would then be a result of  a 
balance between CD28 and CTLA-4-mediated events. 
Our recent results how that, during the course of R-EAE, 
there is preferential upregulation of B7-1, as compared to 
B7-2, both in the CNS and in the splenic lymphoid com- 
partment (24). Such dynamic hanges in costimulatory ligand 
expression during a chronic inflammatory autoimmune re- 
sponse may reflect an attempt at downregulating a destruc- 
tive response. Based on the parallel ate upregulation of B7-1 
and CTLA-4, it has been suggested that B7-1 may be the 
preferred ligand for CTLA-4 (26). Our preliminary data 
suggest hat there are dramatic differences in B7 ligand ex- 
pression depending on the lymphoid tissue examined. It is 
tempting to speculate that certain compartments of the im- 
mune system may be involved in providing an environ- 
ment which promotes pro-inflammatory events, whereas 
other compartments may be primarily responsible for the 
ultimate downregulation of  T cell responses. Our current 
studies are directed towards addressing these issues by care- 
fully following the expression and functions of  B7 mole- 
cules and their T cell ligands in animals with an apparent 
self regulating autoimmune disease such as observed uring 
relapsing-remitting EAE. 
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